Huntington's Disease Market
Huntington's Disease Market Size, Share & Industry Analysis, By Drug Class (Antidopaminergic, Antipsychotic, Antidepressant, Others), By Route of Administration (Oral, Injectable), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Region (North America, Europe, Asia-Pacific, Latin America, Middle East & Africa) -- Share, Size, Outlook, and Opportunity Analysis, 2024-2031
Market Overview
The global Huntington's Disease market is projected to reach USD 1.5 billion by 2031, growing at a CAGR of 8.5% during the forecast period. North America dominated the market in 2023 with a 45% share. The growth is driven by increasing prevalence of Huntington's disease, advancements in diagnosis and treatment, and rising awareness about the disease.
Huntington's Disease Market Dynamics
Market Trend: Gene Therapy and RNA Targeting
Gene therapy and RNA targeting approaches are emerging as promising trends in the Huntington's disease market. These strategies aim to address the underlying genetic cause of the disease by either replacing the faulty gene or silencing the expression of mutant huntingtin protein. Several clinical trials are underway to evaluate the safety and efficacy of gene therapies and antisense oligonucleotides in treating Huntington's disease.
Market Driver: Increasing Prevalence of Huntington's Disease
The increasing prevalence of Huntington's disease worldwide is a key driver for market growth. According to the World Health Organization, the global prevalence of Huntington's disease is estimated to be 2.71 per 100,000 individuals. The rising incidence is attributed to factors such as genetic inheritance, aging population, and improved diagnostic techniques. As more patients are diagnosed with Huntington's disease, the demand for effective treatments is expected to increase.
Market Restraint: High Cost of Treatment
The high cost associated with the treatment of Huntington's disease is a significant restraint for market growth. Currently available therapies, such as antipsychotics and antidepressants, provide symptomatic relief but do not address the underlying cause of the disease. The development of disease-modifying therapies, such as gene therapies and RNA-targeting drugs, involves substantial research and development expenses, which are reflected in the final cost of treatment. The high cost may limit patient access and hinder market adoption in cost-sensitive regions.
Segment Overview
Antipsychotics to Dominate Drug Class segment in Huntington's Disease market
The antipsychotics segment is expected to hold the largest share in the Huntington's disease market throughout the forecast period. Antipsychotic drugs, such as tetrabenazine and deutetrabenazine, are commonly prescribed to manage the movement disorders and psychiatric symptoms associated with Huntington's disease. The efficacy of these drugs in controlling chorea and improving quality of life drives their widespread use in the management of Huntington's disease.
In July 2024, the U.S. FDA approved a new antipsychotic drug, developed by Teva Pharmaceuticals, specifically for the treatment of chorea associated with Huntington's disease. The drug demonstrated significant reduction in chorea symptoms compared to placebo in clinical trials.
According to a study published in the Journal of Neurology, Neurosurgery & Psychiatry in 2023, approximately 60% of Huntington's disease patients receive antipsychotic medications to manage their symptoms.
Regional Outlook
North America holds the largest share in the Huntington's disease market, driven by factors such as high prevalence of the disease, well-established healthcare infrastructure, and increasing adoption of advanced therapies. The U.S. accounts for the majority of the market share, with a large patient population and significant investment in research and development activities.
In March 2024, the Huntington's Disease Society of America (HDSA) launched a new initiative to increase access to genetic testing and counseling services across the U.S., aiming to improve early diagnosis and patient support.
The North American Huntington's disease market was valued at $580 million in 2023 and is projected to reach $1.2 billion by 2031, growing at a CAGR of 9.5% during the forecast period.
Competitive Intelligence
The Huntington's disease market is moderately competitive, with a mix of established pharmaceutical companies and emerging biotech firms. Key players include Teva Pharmaceuticals, Lundbeck, Valeant Pharmaceuticals, Prana Biotechnology, and Ionis Pharmaceuticals. These companies are focusing on developing novel therapies, including gene therapies, RNA-targeting drugs, and neuroprotective agents.
Strategic collaborations and partnerships are crucial for advancing pipeline programs and bringing new therapies to market. In June 2024, Ionis Pharmaceuticals entered into a collaboration agreement with Roche to develop and commercialize an antisense oligonucleotide therapy for Huntington's disease.
Mergers and acquisitions are also reshaping the competitive landscape. In January 2024, Lundbeck acquired a clinical-stage biotech company specializing in gene therapies for neurodegenerative disorders, including Huntington's disease.
The market is witnessing the entry of new players, particularly in the gene therapy and RNA-targeting segments, which are attracting significant investment and research interest. Established players are differentiating themselves through strong clinical trial results, innovative drug delivery systems, and patient support programs.
Analyst Opinion
The Huntington's disease market outlook is promising, driven by the increasing prevalence of the disease, advancements in diagnostic techniques, and the development of novel therapies. While symptomatic treatments, such as antipsychotics and antidepressants, currently dominate the market, the focus is shifting towards disease-modifying approaches that address the underlying genetic cause of Huntington's disease.
Gene therapies and RNA-targeting drugs hold significant potential to transform the treatment landscape for Huntington's disease. However, the high cost and complex manufacturing processes associated with these therapies may pose challenges for widespread adoption. Collaborative efforts between industry, academia, and regulatory authorities will be crucial to accelerate the development and commercialization of these innovative therapies.
As the market evolves, there will be a greater emphasis on personalized medicine approaches, leveraging genetic testing and biomarkers to identify patients who are most likely to benefit from specific therapies. Patient support programs, including genetic counseling and access to multidisciplinary care teams, will play a vital role in improving patient outcomes and quality of life.
Pharmaceutical companies should focus on building strong partnerships with patient advocacy groups, healthcare providers, and payers to ensure broad access to Huntington's disease therapies. Demonstrating the long-term value and cost-effectiveness of novel therapies will be critical for market success.
Major Players
-
Teva Pharmaceuticals
-
Lundbeck
-
Valeant Pharmaceuticals
-
Prana Biotechnology
-
Ionis Pharmaceuticals
-
Roche
-
Wave Life Sciences
-
uniQure
-
Voyager Therapeutics
-
Neurocrine Biosciences
-
Mitsubishi Tanabe Pharma
-
Amneal Pharmaceuticals
Key Developments
-
July 2024: Teva Pharmaceuticals received U.S. FDA approval for a new antipsychotic drug specifically for the treatment of chorea associated with Huntington's disease.
-
March 2024: The Huntington's Disease Society of America (HDSA) launched a new initiative to increase access to genetic testing and counseling services across the U.S.
1. INTRODUCTION
1.1. Market Definitions & Study Assumptions
1.2. Market Research Scope & Segment
1.3. Research Methodology
2. EXECUTIVE SUMMARY
2.1. Market Overview & Insights
2.2. Segment Outlook
2.3. Region Outlook
3. COMPETITIVE INTELLIGENCE
3.1. Companies Financial Position
3.2. Company Benchmarking -- Key Players
3.3. Market Share Analysis -- Key Companies
3.4. Recent Companies Key Activities
3.5. Pricing Analysis
3.6. SWOT Analysis
4. Company Profiles (Key Companies list by Country) (Premium)*
5. COMPANY PROFILES
5.1. Teva Pharmaceuticals
5.2. Lundbeck
5.3. Valeant Pharmaceuticals
5.4. Prana Biotechnology
5.5. Ionis Pharmaceuticals
5.6. Roche
5.7. Wave Life Sciences
5.8. uniQure
5.9. Voyager Therapeutics
5.10. Neurocrine Biosciences
5.11. Mitsubishi Tanabe Pharma
5.12. Amneal Pharmaceuticals (*LIST NOT EXHAUSTIVE)
6. MARKET DYNAMICS
6.1. Market Trends
6.1.1. Gene Therapy and RNA Targeting
6.1.2. Trend 2
6.1.3. Trend 3
6.2. Market Drivers
6.2.1. Increasing Prevalence of Huntington's Disease
6.2.2. Driver 2
6.2.3. Driver 3
6.3. Market Restraints
6.3.1. High Cost of Treatment
6.3.2. Restraint 2
6.4. Market Opportunities
6.5. Porter's Five Forces Analysis
6.5.1. Threat of New Entrants
6.5.2. Bargaining Power of Buyers/Consumers
6.5.3. Bargaining Power of Suppliers
6.5.4. Threat of Substitute Products
6.5.5. Intensity of Competitive Rivalry
6.6. Supply Chain Analysis
6.7. Value Chain Analysis
6.8. Trade Analysis
6.9. Pricing Analysis
6.10. Regulatory Analysis
6.11. Patent Analysis
6.12. SWOT Analysis
6.13. PESTLE Analysis
7. BY DRUG CLASS (MARKET SIZE/VALUE (US$ Mn), SHARE (%), MARKET FORECAST (%), YOY GROWTH (%)-- 2020-2031)
7.1. Antidopaminergic
7.2. Antipsychotic
7.3. Antidepressant
7.4. Others
8. BY ROUTE OF ADMINISTRATION (MARKET SIZE/VALUE (US$ Mn), SHARE (%), MARKET FORECAST (%), YOY GROWTH (%)-- 2020-2031)
8.1. Oral
8.2. Injectable
9. BY DISTRIBUTION CHANNEL (MARKET SIZE/VALUE (US$ Mn), SHARE (%), MARKET FORECAST (%), YOY GROWTH (%)-- 2020-2031)
9.1. Hospital Pharmacies
9.2. Retail Pharmacies
9.3. Online Pharmacies
10. REGION (MARKET SIZE/VALUE (US$ Mn), SHARE (%), MARKET FORECAST (%), YOY GROWTH (%)-- 2020-2031)*
10.1. North America
10.1.1. United States
10.1.2. Canada
10.1.3. Mexico
10.2. South America
10.2.1. Brazil
10.2.2. Argentina
10.2.3. Rest of South America
10.3. Europe
10.3.1. Germany
10.3.2. United Kingdom
10.3.3. France
10.3.4. Italy
10.3.5. Spain
10.3.6. Russia
10.3.7. Rest of Europe
10.4. Asia-Pacific
10.4.1. China
10.4.2. Japan
10.4.3. India
10.4.4. Australia
10.4.5. South Korea
10.4.6. Rest of Asia-Pacific
10.5. Middle-East
10.5.1. UAE
10.5.2. Saudi Arabia
10.5.3. Turkey
10.5.4. Rest of Middle East
10.6. Africa
10.6.1. South Africa
10.6.2. Egypt
10.6.3. Rest of Africa
*NOTE: All the regions mentioned in the scope will be provided with (MARKET SIZE/VALUE (US$ Mn), SHARE (%), MARKET FORECAST (%), YOY GROWTH (%)-- 2020-2031)
BY DRUG CLASS:
- Antidopaminergic
- Antipsychotic
- Antidepressant
- Others
BY ROUTE OF ADMINISTRATION
- Oral
- Injectable
- Others
BY DISTRIBUTION CHANNEL
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
BY REGION
- North America
- Europe
- Asia-Pacific
- Latin America
- Middle East & Africa
Frequently Asked Questions
We at Aurorawave Intellects Market Report gives total market analysis that suit our customer business need and permit decision maker to run organizations without any problem. We have accomplished greatness in giving start to finish market research arrangements. Our detachment of industry specialists accumulate key data and get ready substance that lines up with our customer's business/specialty.
We at aurorawaveintellects.com offer mainly 3 types of licenses:
• Single User: Research Report copy can be distributed to a single user only
• Multi User: Research Report distribution is restricted up to 5 users.
• Corporate License :Research Report can be distributed across the company.
Based on the nature of the topic or research, the formats vary. The different formats of the report are as following:
• Word Document
• PPT
Following modes are available for making the payment:
• Online Payment (Visa Card, Master Card, Stripe)
• Razorpay
• Net Banking
• Bank Wire Transfer
Our customer service and research specialist team are available by phone and by email. Customer service hours are 24X7 Indian Standard Time (IST). You may reach us at:
• Email: info@aurorawaveintellects.com
• United Kingdom: ++91 7382742511